- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2013 (2013), Article ID 398253, 7 pages
Skip Regulates TGF-β1-Induced Extracellular Matrix Degrading Proteases Expression in Human PC-3 Prostate Cancer Cells
1Laboratorio de Biología Celular, Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile, 7810000 Santiago, Chile
2Department of Biology, University of the Balearic Islands, Ctra Valldemossa, Km 7.5 , 07122 Palma de Mallorca, Spain
3Laboratory for Experimental Haematology and Stem Cells, Institute for Medical Research, University of Belgrade, Dr. Subotica 4, P.O. Box 102, 11129 Belgrade, Serbia
Received 19 February 2013; Revised 25 April 2013; Accepted 29 April 2013
Academic Editor: Fazlul H. Sarkar
Copyright © 2013 Victor Villar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. Padua and J. Massagué, “Roles of TGFbeta in metastasis,” Cell Research, vol. 19, pp. 89–102, 2009.
- P. Wikstrom, P. Stattin, I. Franck-Lissbrant, J. E. Damber, and A. Bergh, “Transforming growth factor B1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer,” Prostate, vol. 37, pp. 19–29, 1998.
- N. Sidenius and F. Blasi, “The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy,” Cancer and Metastasis Reviews, vol. 22, no. 2-3, pp. 205–222, 2003.
- M. K. Durand, J. S. Bodker, A. Christensen, et al., “Plasminogen activator inhibitor-1 and tumor growth, invasion, and metastasis,” Thrombosis and Haemostasis, vol. 91, pp. 439–449, 2004.
- E. I. Deryugina and J. P. Quigley, “Matrix metalloproteinases and tumor metastasis,” Cancer and Metastasis Reviews, vol. 25, no. 1, pp. 9–34, 2006.
- K. Dass, A. Ahmad, A. S. Azmi, S. H. Sarkar, and F. H. Sarkar, “Evolving role of uPA/uPAR system in human cancers,” Cancer Treatment Reviews, vol. 34, no. 2, pp. 122–136, 2008.
- C. Festuccia, M. Bologna, C. Vicentini, et al., “Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells,” International Journal of Cancer, vol. 69, pp. 386–393, 1996.
- P. J. Van Veldhuizen, R. Sadasivan, R. Cherian, and A. Wyatt, “Urokinase-type plasminogen activator expression in human prostate carcinomas,” American Journal of the Medical Sciences, vol. 312, no. 1, pp. 8–11, 1996.
- C. Festuccia, A. Angelucci, G. L. Gravina et al., “Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells,” International Journal of Cancer, vol. 85, pp. 407–415, 2000.
- L. Konrad, J. A. Scheiber, L. Schwarz, A. J. Schrader, and R. Hofmann, “TGF-β1 and TGF-β2 strongly enhance the secretion of plasminogen activator inhibitor-1 and matrix metalloproteinase-9 of the human prostate cancer cell line PC-3,” Regulatory Peptides, vol. 155, no. 1–3, pp. 28–32, 2009.
- G. M. Leong, N. Subramaniam, J. Figueroa et al., “Ski-interacting protein interacts with Smad proteins to augment transforming growth factor-beta-dependent transcription,” The Journal of Biological Chemistry, vol. 276, no. 21, pp. 18243–18248, 2001.
- P. Folk, F. Půta, and M. Skružný, “Transcriptional coregulator SNW/SKIP: the concealed tie of dissimilar pathways,” Cellular and Molecular Life Sciences, vol. 61, no. 6, pp. 629–640, 2004.
- V. Villar, J. Kocic, D. Bugarski, G. Jovcic, and J. F. Santibanez, “SKIP is required for TGF-β1-induced epithelial mesenchymal transition and migration in transformed keratinocytes,” FEBS Letters, vol. 584, no. 22, pp. 4586–4592, 2010.
- J. F. Santibáñez, A. Navarro, and J. Martínez, “Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines,” Anticancer Research, vol. 17, no. 2, pp. 1199–1204, 1997.
- J. F. Santibáñez, P. Frontelo, M. Iglesias, J. Martínez, and M. Quintanilla, “Urokinase expression and binding activity associated with the transforming growth factor beta1-induced migratory and invasive phenotype of mouse epidermal keratinocytes,” Journal of Cellular Biochemistry, vol. 74, pp. 61–73, 1999.
- J. Francisco Santibáez, J. Guerrero, M. Quintanilla, A. Fabra, and J. Martínez, “Transforming growth factor-β1 modulates matrix metalloproteinase-9 production through the Ras/MAPK signaling pathway in transformed keratinocytes,” Biochemical and Biophysical Research Communications, vol. 296, no. 2, pp. 267–273, 2002.
- D. Bello-DeOcampo and D. J. Tindall, “TGF-β/smad signaling in prostate cancer,” Current Drug Targets, vol. 4, no. 3, pp. 197–207, 2003.
- J. Kocic, D. Bugarski, and J. F. Santibanez, “SMAD3 is essential for transforming growth factor-β1-induced urokinase type plasminogen activator expression and migration in transformed keratinocytes,” European Journal of Cancer, vol. 48, pp. 1550–1557, 2012.
- M. Koziczak, W. Krek, and Y. Nagamine, “Pocket protein-independent repression of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 gene expression by E2F1,” Molecular and Cellular Biology, vol. 20, no. 6, pp. 2014–2022, 2000.
- J. Y. Yao, Y. Wang, J. An et al., “Mutation analysis of the Smad3 gene in human osteoarthritis,” European Journal of Human Genetics, vol. 11, no. 9, pp. 714–717, 2003.
- P. Bonniaud, M. Kolb, T. Galt et al., “Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis,” Journal of Immunology, vol. 173, no. 3, pp. 2099–2108, 2004.